Company profile: Mynd Life Sciences
1.1 - Company Overview
Company description
- Provider of biomarker diagnostic tests for postpartum depression and early Alzheimer’s detection, psilocybin-based drug R&D targeting central nervous system diseases, and intellectual property on inflammation-regulating gene pathways to support treatments for neuroinflammatory diseases; also developing at-home tests to monitor inflammation and aid health management.
Products and services
- Psilocybin Drug Development: Advances novel-psychedelic therapeutics to treat central nervous system diseases by actively modifying disease outcomes, building pharmaceutical candidates based on psilocybin chemistry
- AD Biomarker Test: Delivers blood-based diagnostics by identifying specific inflammation-related proteins linked to Alzheimer’s Disease, enabling early detection of the condition
- PPD Biomarker Test: Supplies blood-based diagnostics that detect specific proteins associated with postpartum depression, enabling early diagnosis to guide timely clinical evaluation for maternal mental health
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Mynd Life Sciences
MyndTec
HQ: Canada
Website
- Description: Provider of medical devices focused on the treatment of stroke, spinal cord injury (SCI), and other brain-related disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MyndTec company profile →
Burl Concepts
HQ: United States
Website
- Description: Provider of a portable, battery-powered ultrasound device for non-invasive, transcranial brain perfusion assessment and stroke diagnosis. The SONAS system uses microbubble contrast agents to detect cerebral blood perfusion differences.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Burl Concepts company profile →
Freespira
HQ: United States
Website
- Description: Provider of the only FDA-cleared, at-home, drug-free digital therapeutic proven to significantly reduce or eliminate panic attacks, panic disorder, and PTSD symptoms in 28 days. The Freespira treatment uses a sensor and tablet to normalize breathing. Also offers resources for health plans, employees, and individuals, a veterans relief program, and a provider referral program with insurance coverage information.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Freespira company profile →
Psyence Biomed
HQ: Canada
Website
- Description: Provider of nature-derived psilocybin-based psychedelic medicines focused on mental health disorders in palliative care. Conducts Phase IIb clinical trials of natural psilocybin for Adjustment Disorder with psychotherapy and varied dosages, and plans a clinical trial for Alcohol Use Disorder with a focus on Substance Use Disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Psyence Biomed company profile →
Shape Therapeutics
HQ: United States
Website
- Description: Provider of AI-enabled RNA therapeutics and gene therapy technologies, including the ShapeTX AI Engine for data-driven medicine development; RNA Medicines for discovery and design; RNAfix recruiting ADAR to recode RNA; RNAskip suppressor tRNA addressing premature stop codons; RNAswap smart-sensing vectors for tailored gene expression; and Precise Delivery engineered capsids for targeted RNA delivery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Shape Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Mynd Life Sciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Mynd Life Sciences
2.2 - Growth funds investing in similar companies to Mynd Life Sciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Mynd Life Sciences
4.2 - Public trading comparable groups for Mynd Life Sciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →